platinum has been researched along with Carcinoma in 53 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 5 (9.43) | 18.7374 |
1990's | 18 (33.96) | 18.2507 |
2000's | 3 (5.66) | 29.6817 |
2010's | 14 (26.42) | 24.3611 |
2020's | 13 (24.53) | 2.80 |
Authors | Studies |
---|---|
Davidson, B; Elstrand, MB | 1 |
Cheong, TF; Chiang, KY; Ho, JCM; Ip, MSM; Kwok, WC; Lam, DCL; Tam, TCC | 1 |
Banda, K; Chandok, H; Dobrolecki, L; Kumar, P; Lewis, MT; Liu, ET; Menghi, F; Radke, MR; Rodriguez, IV; Somlo, G; Straub, R; Swisher, EM; Yost, SE; Yuan, Y | 1 |
Ermini, ML; Gonnelli, A; Mapanao, AK; Menicagli, M; Santi, M; Sarogni, P; Voliani, V; Zamborlin, A | 1 |
Aghajanian, C; Clamp, AR; Coleman, RL; Colombo, N; Dean, A; Fong, PC; Gancedo, MA; Goble, S; Goh, JC; Holloway, RW; Kwan, T; Leary, A; Ledermann, JA; Lin, KK; Lorusso, D; Maloney, L; O'Malley, DM; Oaknin, A; Oza, AM; Scambia, G; Swisher, EM; Weberpals, JI | 1 |
Fu, HC; Huang, YC; Kao, CH; Lan, J; Lin, H; Liu, CT; Ou, YC; Wu, CH | 1 |
Alidra, A; Rambeau, A; Riot, A | 1 |
Li, Z; Liu, XM; Qiao, X; Shi, SH; Xu, JY | 1 |
Barth, MC; Häfner, N; Runnebaum, IB; Weigand, W | 1 |
Buttitta, F; D'Angelo, E; Di Marino, P; Felicioni, L; Ferro, B; Marchetti, A; Pasciuto, MP; Primavera, FC; Rossetti, R; Tudini, M; Zampacorta, C | 1 |
Aghajanian, C; Armstrong, DK; Banerjee, S; Cameron, T; Clamp, AR; Coleman, RL; Colombo, N; Dean, A; Fong, PC; Gancedo, MA; García-Donas, J; Goble, S; Goh, JC; Holloway, RW; Leary, A; Ledermann, JA; Lorusso, D; Maloney, L; O'Malley, DM; Oaknin, A; Oza, AM; Scambia, G; Swisher, EM; Weberpals, JI | 1 |
Adawi, R; Gopas, J; Khamaisi, H; Koren Carmi, Y; Mahajna, J; Mahmoud, H | 1 |
Cavalieri, S; Licitra, L | 1 |
Ebbesson, A; Hartman, L; Hedenfalk, I; Jönsson, JM; Malander, S; Martín de la Fuente, L; Måsbäck, A; Nilbert, M | 1 |
Ambriović-Ristov, A; Arany, I; Brozovic, A; Fiket, Z; Fritz, G; Köberle, B; Majhen, D; Osmak, M; Polančac, DS; Vuković, L | 1 |
Chen, X; Feng, J; Guan, X; Hong, Y; Song, H; Ye, J; You, X; Zheng, P | 1 |
Hasegawa, K; Ichikawa, R; Kato, R; Kawamura, K; Oe, S; Torii, Y; Udagawa, Y | 1 |
Chatterjee, PK; Gupta, M; Kohn, N; Metz, CN; Rosales, I; Solanki, MH; Xue, X; Yeboah, MM | 1 |
Chai, A; Dai, R; Li, H; Zhang, Z | 1 |
Dong, M; Gui, L; He, X; Hu, S; Jia, B; Liu, P; Qin, Y; Yang, J; Yang, S; Zhang, C; Zhou, S | 1 |
Di Palma, M; Guillot, A; Médioni, J; Spaeth, D; Théodore, C | 1 |
Chen, IS; Kirn, D; Lee, JY; Lin, TK; Liu, TC; Tsao, CJ | 1 |
Blank, H; Bräse, S; Brenner, P; Crone, M; Esselen, M; Gehrke, H; Gerthsen, D; Marko, D; Muller, T; Pelka, J; Schneider, R; Send, W; Türk, M; Zibat, V | 1 |
Güth, U; Huang, DJ; Schötzau, A; Wight, E | 1 |
Fernandez, G; Garnier, R; Hasni-Pichard, H; Konate, A; Mezzaroba, D; Pocard, M; Poupon, J; Villa, A | 1 |
Clamp, AR; Evans, S; Griffiths, RW; Hasan, J; Jayson, GC; Kumaran, GC; Mitchell, CL; Welch, RS; Zee, YK | 1 |
Iramaneerat, K; Khemapech, N; Mutirangura, A; Rattanatunyong, P; Triratanachat, S | 1 |
Pavlidis, N | 1 |
Blair, E; Cohen, EE; Golden, DW; Haraf, DJ; Nwizu, T; Rudra, S; Stenson, KM; Vokes, EE; Witt, ME | 1 |
Alvarez, RD; Barnes, MN; Huh, WK; Kilgore, LC; Leath, CA; Partridge, EE; Rocconi, RP; Straughn, JM | 1 |
Hayashi, S; Kano, E; Matsumoto, H; Ohtsubo, T; Saito, H; Saito, T; Sugimoto, C; Tanaka, N | 1 |
Li, M; Liu, J | 1 |
Alimonti, A; Bedini, AV; Canevali, C; Caroli, S; Milani, F; Morazzoni, F; Moschetti, I; Petrucci, F; Ravasi, G; Todeschini, R | 1 |
Gore, ME; Taylor, AE | 1 |
Hoskins, PJ; Swenerton, KD | 1 |
Funakoshi, T; Kojima, S; Shimada, H; Takahashi, K | 1 |
Barakat, RR; Curtin, JP; Hakes, TB; Hoskins, WJ; Rubin, SC; Wong, GY | 1 |
Armstrong, D; Carmichael, J; Gordon, A; Malfetano, J; ten Bokkel Huinink, W | 1 |
Holford, J; Kelland, LR; Rogers, P | 1 |
Chaney, SG; Luo, FR; Wyrick, SD | 1 |
Besmaine, A; Cuvier, C; Cvitkovic, E; Dupont-André, G; Goldwasser, F; Kalla, S; Lokiec, F; Mahjoubi, M; Marty, M; Méry-Mignard, D; Misset, JL; Ouldkaci, M; Wasserman, E | 1 |
Hunakova, L; Kelland, LR; O'Neill, CF | 1 |
Caserini, C; Colangelo, D; Farrell, N; Gatti, L; Leone, R; Perego, P; Spinelli, S; Supino, R; Zunino, F | 1 |
Aggarwal, SK; McAllister, PK; Rosenberg, B; Wagner, RW | 1 |
Klys, HS; Matheson, LM; McKay, K; Smyth, JF; Tothill, P | 1 |
Almadrones, L; Hakes, T; Hoskins, W; Jones, W; Lewis, JL; Markman, M; Pizzuto, F; Reichman, B; Rubin, S | 1 |
Daoud, SS; Forde, NH | 1 |
Cavaletti, G; Minoia, A; Pizzini, G; Tredici, G | 1 |
Chambers, JT; Chambers, SK; Schwartz, PE; Voynick, IM | 1 |
Elferink, F; Gall, HE; Klein, I; Pinedo, HM; van der Vijgh, WJ; Vermorken, JB | 1 |
Andrews, PA; Howell, SB; Mann, SC; Velury, S | 1 |
Chambers, JT; Chambers, SK; Kohorn, EI; Lawrence, R; Schwartz, PE | 1 |
Andrews, PA; Howell, SB; Murphy, MP | 1 |
2 review(s) available for platinum and Carcinoma
Article | Year |
---|---|
Concurrent chemoradiotherapy comparison of taxanes and platinum versus 5-fluorouracil and platinum in nasopharyngeal carcinoma treatment.
Topics: Carcinoma; Chemoradiotherapy; Fluorouracil; Humans; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Platinum; Taxoids; Treatment Outcome | 2014 |
Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Multicenter Studies as Topic; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Platinum; Remission Induction; Safety; Survival Rate; Topoisomerase I Inhibitors; Topotecan | 1997 |
5 trial(s) available for platinum and Carcinoma
Article | Year |
---|---|
Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma.
Topics: Antineoplastic Agents; Carcinoma; Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors | 2022 |
Determination of platinum in plasma of patients affected by inoperable lung carcinoma treated with radiotherapy and concurrent low-dose continuous infusion of cis-dichlorodiammine platinum(II).
Topics: Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Computer Simulation; Humans; Infusions, Intravenous; Lung Neoplasms; Mass Spectrometry; Platinum | 1995 |
Oral etoposide is active against platinum-resistant epithelial ovarian cancer.
Topics: Administration, Oral; Adult; Aged; Carcinoma; Drug Resistance; Etoposide; Female; Humans; Middle Aged; Ovarian Neoplasms; Platinum; Treatment Outcome | 1994 |
Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Digestive System Neoplasms; Dose-Response Relationship, Drug; Female; Gilbert Disease; Glucuronates; Glucuronides; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Platinum; Treatment Outcome | 1999 |
Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease.
Topics: Acute Kidney Injury; Adult; Aged; Carcinoma; Drug Evaluation; Drug Resistance; Female; Humans; Ifosfamide; Mesna; Middle Aged; Ovarian Neoplasms; Platinum | 1992 |
46 other study(ies) available for platinum and Carcinoma
Article | Year |
---|---|
Clinicopathological prognostic parameters in patients with tubo-ovarian carcinoma effusions.
Topics: Biomarkers, Tumor; Carcinoma; Cystadenocarcinoma, Serous; Female; Humans; Ovarian Neoplasms; Platinum; Pleural Effusion, Malignant; Prognosis; Retrospective Studies | 2022 |
Clinical efficacy and safety of pemetrexed with or without either Bevacizumab or Pembrolizumab in patients with metastatic nonsquamous non-small cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Humans; Lung Neoplasms; Pemetrexed; Platinum; Retrospective Studies; Treatment Outcome | 2023 |
Genomic and epigenomic
Topics: BRCA1 Protein; BRCA2 Protein; Carcinoma; Epigenomics; Female; Genomics; Humans; Mutation; Ovarian Neoplasms; Platinum; Triple Negative Breast Neoplasms | 2022 |
Pro-apoptotic and size-reducing effects of protein corona-modulating nano-architectures enclosing platinum prodrug in
Topics: Antineoplastic Agents; Carcinoma; Caspase 3; Cell Line, Tumor; Humans; Nanoparticles; Peptides; Platinum; Prodrugs; Protein Corona; Transferrin; Vascular Endothelial Growth Factor A | 2022 |
Case report: Durable response after pembrolizumab in combination with radiation - induced abscopal effect in platinum - refractory metastatic endometrial clear cell carcinoma.
Topics: Antibodies, Monoclonal, Humanized; Carcinoma; Female; Humans; Platinum; Uterine Neoplasms | 2022 |
Metastatic lymphoepithelial carcinoma of the parotid gland: A case of prolonged response with platinum-gemcitabine regimen.
Topics: Carcinoma; Gemcitabine; Humans; Parotid Gland; Parotid Neoplasms; Platinum | 2023 |
Blocking xCT and PI3K/Akt pathway synergized with DNA damage of Riluzole-Pt(IV) prodrugs for cancer treatment.
Topics: Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Cisplatin; DNA Damage; Humans; Phosphatidylinositol 3-Kinases; Platinum; Prodrugs; Proto-Oncogene Proteins c-akt; Riluzole | 2023 |
Synthesis, Characterization and Biological Investigation of the Platinum(IV) Tolfenamato Prodrug-Resolving Cisplatin-Resistance in Ovarian Carcinoma Cell Lines.
Topics: Antineoplastic Agents; Carcinoma; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cisplatin; Female; Humans; Ovarian Neoplasms; Platinum; Prodrugs | 2023 |
BRCA gene amplification in primary peritoneal high-grade serous carcinoma patient with intrinsic resistance to platinum treatment: a case report.
Topics: BRCA1 Protein; BRCA2 Protein; Carcinoma; Female; Gene Amplification; Humans; Mutation; Ovarian Neoplasms; Platinum | 2023 |
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Disease Progression; Double-Blind Method; Female; Humans; Indoles; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Treatment Outcome | 2020 |
Flavonoids Restore Platinum Drug Sensitivity to Ovarian Carcinoma Cells in a Phospho-ERK1/2-Dependent Fashion.
Topics: 3T3-L1 Cells; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Flavonoids; Humans; MAP Kinase Signaling System; Mice; Ovarian Neoplasms; Paclitaxel; Platinum; Tumor Microenvironment | 2020 |
Next generation platinum salt in nasopharygeal carcinoma.
Topics: Carcinoma; Chemoradiotherapy; Cisplatin; Cyclobutanes; Fluorouracil; Humans; Induction Chemotherapy; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Organoplatinum Compounds; Platinum | 2021 |
Claudin-4 Expression is Associated With Survival in Ovarian Cancer But Not With Chemotherapy Response.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; BRCA1 Protein; BRCA2 Protein; Carcinoma; Carcinoma, Ovarian Epithelial; Claudin-4; Cohort Studies; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Prognosis; Sweden; Tissue Array Analysis | 2018 |
Endoplasmic reticulum stress is involved in the response of human laryngeal carcinoma cells to Carboplatin but is absent in Carboplatin-resistant cells.
Topics: Apoptosis; Blotting, Southwestern; Blotting, Western; Carboplatin; Carcinoma; Cell Line, Tumor; Cell Survival; Cinnamates; Cyclic N-Oxides; DNA Primers; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Gene Silencing; Humans; Laryngeal Neoplasms; Platinum; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Signal Transduction; Spin Labels; Thiourea | 2013 |
Retrospective comparative study of irinotecan and pegylated liposomal doxorubicin for platinum-resistant or -refractory epithelial ovarian and primary peritoneal carcinoma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Middle Aged; Neoplasms, Glandular and Epithelial; Neutropenia; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Polyethylene Glycols; Retrospective Studies; Salvage Therapy; Treatment Outcome | 2014 |
Magnesium protects against cisplatin-induced acute kidney injury without compromising cisplatin-mediated killing of an ovarian tumor xenograft in mice.
Topics: Acute Kidney Injury; Animals; Antineoplastic Agents; Carcinoma; Cation Transport Proteins; Cell Line, Tumor; Cisplatin; Dietary Supplements; Female; Gene Expression; Humans; Kidney; Magnesium; Mice, Nude; Ovarian Neoplasms; Platinum; Xenograft Model Antitumor Assays | 2015 |
Photoinduced cytotoxicity by a platinum diimine complex employing magnetite-silica nanocomposites as delivery vehicles.
Topics: Carcinoma; Cell Line, Tumor; Drug Delivery Systems; Dynamic Light Scattering; Ferrosoferric Oxide; Humans; Light; Microscopy, Electron, Transmission; Nanocomposites; Photosensitizing Agents; Platinum; Silicon Dioxide; Spectroscopy, Fourier Transform Infrared; Tartrates; X-Ray Diffraction | 2015 |
[Efficacy and safety evaluation of gemcitabine combined with ifosfamide in patients with advanced nasopharyngeal carcinoma after failure of platinum-based chemotherapy].
Topics: Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Ifosfamide; Induction Chemotherapy; Kaplan-Meier Estimate; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neutropenia; Platinum; Remission Induction; Salvage Therapy; Survival Rate; Thrombocytopenia; Treatment Failure | 2015 |
Efficacy and safety of Vinflunine for advanced or metastatic urothelial carcinoma in routine practice based on the French multi-centre CURVE study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Platinum; Retrospective Studies; Urologic Neoplasms; Urothelium; Vinblastine | 2016 |
Erythema elevatum diutinum as a paraneoplastic syndrome in a patient with pulmonary lymphoepithelioma-like carcinoma.
Topics: Antineoplastic Agents; Biopsy; Carcinoma; Erythema; Female; Humans; Lung; Lung Neoplasms; Middle Aged; Paraneoplastic Syndromes; Platinum; Remission Induction; Skin; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Cellular uptake of platinum nanoparticles in human colon carcinoma cells and their impact on cellular redox systems and DNA integrity.
Topics: Carcinoma; Cell Line, Tumor; Colonic Neoplasms; Comet Assay; DNA Damage; DNA-Formamidopyrimidine Glycosylase; Glutathione; Humans; Metal Nanoparticles; Microscopy, Electron, Transmission; Particle Size; Platinum; Reactive Oxygen Species | 2009 |
Is the current concept of recurrent ovarian carcinoma as a chronic disease also applicable in platinum resistant patients?
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma; Cohort Studies; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Retrospective Studies | 2010 |
Evaluation of environmental contamination by platinum and exposure risks for healthcare workers during a heated intraperitoneal perioperative chemotherapy (HIPEC) procedure.
Topics: Air Pollutants, Occupational; Antineoplastic Agents; Carcinoma; Combined Modality Therapy; Environmental Monitoring; Gloves, Surgical; Humans; Hyperthermia, Induced; Infusions, Parenteral; Inhalation Exposure; Medical Staff, Hospital; Occupational Exposure; Operating Rooms; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Platinum | 2011 |
Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; CA-125 Antigen; Carcinoma; Carcinoma, Ovarian Epithelial; Cisplatin; Cytotoxins; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Platinum; Polyethylene Glycols; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2011 |
HERV-K hypomethylation in ovarian clear cell carcinoma is associated with a poor prognosis and platinum resistance.
Topics: Adult; Biomarkers; Carcinoma; DNA Methylation; Drug Resistance, Neoplasm; Endogenous Retroviruses; Female; Gene Expression; Humans; Kaplan-Meier Estimate; Long Interspersed Nucleotide Elements; Middle Aged; Ovarian Neoplasms; Platinum; Prognosis; Restriction Mapping; Survival Analysis | 2011 |
Optimal therapeutic management of patients with distinct clinicopathological cancer of unknown primary subsets.
Topics: Adenocarcinoma; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Fluorouracil; Humans; Lymphatic Metastasis; Neoplasms, Unknown Primary; Platinum; Prognosis; Taxoids; Treatment Outcome | 2012 |
Outcomes of induction chemotherapy followed by concurrent chemoradiation for nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Adjuvant; Child; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Hydroxyurea; Induction Chemotherapy; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Platinum; Radiotherapy Dosage; Remission Induction; Survival Rate; Treatment Outcome; Young Adult | 2013 |
Pegylated liposomal doxorubicin consolidation therapy after platinum/paclitaxel-based chemotherapy for suboptimally debulked, advanced-stage epithelial ovarian cancer patients.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Platinum; Polyethylene Glycols; Time Factors | 2006 |
Enhancement of cisplatin sensitivity and platinum uptake by 40 degrees C hyperthermia in resistant cells.
Topics: Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Humans; Hyperthermia, Induced; Maxillary Neoplasms; Platinum | 1997 |
[The study of platinum concentration in retroperitoneal lymph nodes after intraperitoneal carboplatin in ovarian tumors].
Topics: Adult; Aged; Carboplatin; Carcinoma; Cystadenocarcinoma, Mucinous; Female; Humans; Infusions, Parenteral; Lymph Nodes; Middle Aged; Ovarian Neoplasms; Platinum; Retroperitoneal Space | 1995 |
Chlorambucil for platinum-refractory ovarian cancer.
Topics: Adult; Aged; Carcinoma; Chlorambucil; Combined Modality Therapy; Drug Resistance; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Remission Induction; Retrospective Studies; Survival Rate | 1994 |
Protective effects of dithiocarbamates against toxicity of cis-diamminedichloroplatinum in mice.
Topics: Animals; Aspartate Aminotransferases; Blood Urea Nitrogen; Carcinoma; Chelating Agents; Cisplatin; Colonic Neoplasms; Diarrhea; Male; Mice; Mice, Inbred Strains; Neoplasm Transplantation; Platinum; Thiocarbamates; Tissue Distribution | 1993 |
Platinum-based chemotherapy of high-risk stage I epithelial ovarian cancer following comprehensive surgical staging.
Topics: Adolescent; Adult; Aged; Carcinoma; Cisplatin; Combined Modality Therapy; Female; Humans; Middle Aged; Ovarian Neoplasms; Platinum; Retrospective Studies; Survival Rate | 1993 |
ras mutation and platinum resistance in human ovarian carcinomas in vitro.
Topics: Carcinoma; Drug Resistance, Neoplasm; Female; Genes, ras; Humans; Mutation; Ovarian Neoplasms; Platinum; Tumor Cells, Cultured | 1998 |
Cytotoxicity, cellular uptake, and cellular biotransformations of oxaliplatin in human colon carcinoma cells.
Topics: Antineoplastic Agents; Biotransformation; Carcinoma; Colonic Neoplasms; DNA Adducts; Humans; Organoplatinum Compounds; Oxaliplatin; Platinum; Tumor Cells, Cultured | 1998 |
Cellular pharmacology of cis and trans pairs of platinum complexes in cisplatin-sensitive and -resistant human ovarian carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma; Cell Division; Cisplatin; DNA Adducts; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Growth Inhibitors; Humans; Organoplatinum Compounds; Ovarian Neoplasms; Platinum; Stereoisomerism; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1999 |
The cellular basis of the efficacy of the trinuclear platinum complex BBR 3464 against cisplatin-resistant cells.
Topics: Adaptor Proteins, Signal Transducing; Adenosine Triphosphatases; Antineoplastic Agents; Base Pair Mismatch; Bone Neoplasms; Carcinoma; Carrier Proteins; Cisplatin; Colonic Neoplasms; Cross-Linking Reagents; DNA Polymerase beta; DNA Repair; DNA Repair Enzymes; DNA-Binding Proteins; DNA, Neoplasm; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Mismatch Repair Endonuclease PMS2; MutL Protein Homolog 1; MutS Homolog 2 Protein; Neoplasm Proteins; Nuclear Proteins; Organoplatinum Compounds; Osteosarcoma; Platinum; Proteins; Proto-Oncogene Proteins; Tumor Cells, Cultured | 1999 |
Cell-surface-associated nucleic acid in tumorigenic cells made visible with platinum-pyrimidine complexes by electron microscopy.
Topics: Animals; Carcinoma; Cattle; Cell Line; Cell Membrane; Cell Nucleolus; Chickens; Chromatin; Cricetinae; DNA; Fibroblasts; Humans; Leukemia L1210; Mice; Microscopy, Electron; Mouth Neoplasms; Platinum; Pyrimidines; Rats; Ribosomes; Sarcoma 180; Staining and Labeling; T-Lymphocytes | 1975 |
The long-term retention of platinum in human tissues following the administration of cisplatin or carboplatin for cancer chemotherapy.
Topics: Adolescent; Adult; Aged; Carboplatin; Carcinoma; Cisplatin; Erythrocytes; Female; Humans; Liver; Male; Middle Aged; Osteosarcoma; Ovarian Neoplasms; Platinum; Teratoma; Testicular Neoplasms; Time Factors | 1992 |
Synergistic cytotoxic actions of cisplatin and liposomal valinomycin on human ovarian carcinoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cell Line; Cell Survival; Cisplatin; Drug Carriers; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Liposomes; Ovarian Neoplasms; Platinum; Tumor Cells, Cultured; Valinomycin | 1991 |
Tissue platinum concentrations and cisplatin schedules.
Topics: Animals; Carcinoma; Cisplatin; Drug Administration Schedule; Female; Ganglia, Spinal; Injections, Intraperitoneal; Ovarian Neoplasms; Peripheral Nerves; Platinum; Rats | 1990 |
Neoadjuvant chemotherapy in stage X ovarian carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Humans; Neoplasm Staging; Ovarian Neoplasms; Platinum; Survival Analysis | 1990 |
Pharmacokinetics of carboplatin after i.v. administration.
Topics: Carboplatin; Carcinoma; Female; Humans; Injections, Intravenous; Organoplatinum Compounds; Ovarian Neoplasms; Platinum | 1987 |
cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells.
Topics: Carcinoma; Cell Membrane; Cisplatin; Dinitrophenols; Drug Resistance; Female; Humans; Ouabain; Ovarian Neoplasms; Platinum; Tumor Cells, Cultured | 1988 |
Evaluation of the role of second-look surgery in ovarian cancer.
Topics: Adolescent; Adult; Aged; Carcinoma; Combined Modality Therapy; Evaluation Studies as Topic; False Negative Reactions; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Platinum; Prognosis; Regression Analysis; Reoperation; Retrospective Studies; Surgical Procedures, Operative; Time Factors | 1988 |
Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells.
Topics: Cadmium; Carcinoma; Cell Compartmentation; Cells, Cultured; Cisplatin; Drug Resistance; Female; Glutathione; Humans; Metallothionein; Ovarian Neoplasms; Platinum; Zinc | 1987 |